| scholarly article | Q13442814 |
| P2093 | author name string | Pamela Samson | |
| A Craig Lockhart | |||
| P2860 | cites work | Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer | Q27320322 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Trastuzumab--mechanism of action and use in clinical practice | Q29615810 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer | Q34051972 | ||
| The HER-2/neu oncogene in tumors of the gastrointestinal tract | Q34311106 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. | Q34346068 | ||
| A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. | Q34398347 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target | Q35650167 | ||
| Association of MTOR and AKT Gene Polymorphisms with Susceptibility and Survival of Gastric Cancer | Q35758788 | ||
| Epidemiology of esophageal adenocarcinoma. | Q36318338 | ||
| EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms | Q36821522 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer | Q37709811 | ||
| Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. | Q38030442 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight | Q38388088 | ||
| Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. | Q38412375 | ||
| Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). | Q38435643 | ||
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Q38829062 | ||
| Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 | ||
| MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells | Q39413378 | ||
| Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Relation between outcomes and localisation of p-mTOR expression in gastric cancer. | Q41926168 | ||
| The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study | Q43500705 | ||
| Trends in incidence of oesophageal and stomach cancer subtypes in Europe. | Q45117256 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study. | Q51056600 | ||
| Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. | Q51056791 | ||
| Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. | Q53598605 | ||
| Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. | Q54391771 | ||
| Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. | Q54578578 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| Encouraging results for PD-1 inhibition in gastric cancer | Q61867568 | ||
| The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas | Q77386062 | ||
| Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus | Q79401515 | ||
| Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome | Q79522451 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis | Q84328266 | ||
| Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer | Q86272493 | ||
| Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial | Q87206964 | ||
| Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma | Q87993642 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 418-429 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Biologic therapy in esophageal and gastric malignancies: current therapies and future directions | |
| P478 | volume | 8 |
| Q58850416 | Angiogenic factors: role in esophageal cancer, a brief review |
| Q58772394 | Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors |
| Q49678076 | Genomic alterations of ERBB receptors in cancer: clinical implications |
| Q58748552 | Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report |
| Q92697387 | MicroRNA-449b-5p Suppresses Proliferation, Migration, and Invasion of Osteosarcoma by Targeting c-Met |
| Q90526354 | Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways |
Search more.